Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome

Area of Science:

• Regenerative medicine
• Cardiology
• Congenital heart disease

Background:

• Myocardial dysfunction is a significant challenge post-Fontan palliation for univentricular congenital heart disease.
• Current medical treatments offer limited efficacy, often leading to cardiac transplant as the final option.
• Cell-based therapies represent a promising frontier for managing heart failure, with ongoing clinical trials in congenital heart disease.

Observation:

• This case study details the first administration of autologous bone marrow-derived mononuclear cells for ventricular dysfunction.
• The patient had undergone a Fontan operation 23 years prior for hypoplastic left heart syndrome.
• Cells were delivered via cardiac catheterization into the coronary circulation.

Findings:

• A decrease in ventricular size was observed post-cell administration.
• Key parameters reflecting ventricular function showed improvement.
• The most significant functional changes were noted at 3 months after cell delivery.

Implications:

• Autologous bone marrow cell therapy shows potential as a regenerative treatment for ventricular dysfunction in Fontan survivors.
• This approach may offer a strategy to delay or prevent the need for cardiac transplantation.
• Further research into cell-based therapies is warranted for complex congenital heart conditions.